PARP1 and cervical cancer: In clinical trials, PARP inhibitors are used either as monotherapy for the treatment of BRCA-mutated cancers or in combination with other chemotherapeutics for the treatment of solid cancers such as pancreatic, colorectal and cervical cancer (39).